Physician profile
Amber Johnson
NPI 1700310877
$508.34
in general payments reported to CMS, 2019-2025
12 companies · $58.79 in 2025
The $58.79 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $171 · 2022: $92.09 · 2023: $121 · 2024: $66.39 · 2025: $58.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $245.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $146.32 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $99.73 | 2021-2023 | Spravato, Invega, Invega Trinza |
| Melinta Therapeutics, LLC | $45.28 | 2024-2025 | Kimyrsa, Orbactiv |
| Kowa Pharmaceuticals America, INC. | $44.88 | 2022-2023 | Seglentis |
| Boston Scientific Corporation | $36.52 | 2024 | Wavewriter Alpha Prime 16 |
| Smith+Nephew, INC. | $23.70 | 2025 | Collagenase Santyl |
| Lilly USA, LLC | $22.14 | 2021 | |
| Alkermes, INC. | $18.89 | 2023 | Aristada, Aristada Initio |
| Allergan, INC. | $18.49 | 2021 | |
| Bioventus LLC | $18.47 | 2023 | Durolane |
| Eisai INC. | $18.39 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.